Clinical Trials
12 trialsNCT02766699 2025-06-03
CerebralEDV
Engeneic Pty Limited
Phase 1 Completed
NCT04774952 2025-04-15
Dose Escalation of RMC-5552 Monotherapy in Relapsed/Refractory Solid Tumors
Revolution Medicines, Inc.
Phase 1 Completed
NCT02164461 2024-05-20
Axalimogene Filolisbac (ADXS11-001) High Dose in Women With Human Papillomavirus (HPV) + Cervical Cancer
Advaxis, Inc.
Phase 1 Completed
NCT02578797 2023-11-09
A JNJ-56021927 (ARN-509; Apalutamide) QT/QTc Study
Aragon Pharmaceuticals, Inc.
Phase 1 Completed
NCT04299880 2023-11-08
Rollover Study to Provide Continued Access to Napabucasin for Patients Enrolled in Boston Biomedical-sponsored Protocols
Sumitomo Pharma America, Inc.
Phase 1 Completed
NCT01594398 2021-11-19
ENCORE110
Syndax Pharmaceuticals
Phase 1 Completed
NCT01966289 2021-03-30
SGI-110 in Combination With an Allogeneic Colon Cancer Cell Vaccine (GVAX) and Cyclophosphamide (CY) in Metastatic Colorectal Cancer (mCRC)
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1 Completed
NCT01999985 2020-11-27
Phase I Trial of Afatinib (BIBW 2992) and Dasatinib in Non-small Cell Lung Cancer (NSCLC)
H. Lee Moffitt Cancer Center and Research Institute
Phase 1 Completed
NCT01294826 2015-06-08
Study of AUY922 and Cetuximab in Patients With KRAS Wild-Type Metastatic Colorectal Cancer
Swedish Medical Center
Phase 1 Completed
NCT01629758 2015-03-06
Safety Study of IL-21/Anti-PD-1 Combination in the Treatment of Solid Tumors
Bristol-Myers Squibb
Phase 1 Completed
NCT00969410 2012-04-12
A Pharmacodynamic Study of AV-299 (Formerly SCH 900105) in Subjects With Advanced Solid Tumors Who Have Liver Metastases
AVEO Pharmaceuticals, Inc.
Phase 1 Completed
NCT00562224 2011-09-28
Study of the Safety and Tolerability of Oral Capsule Form of PCI-24781 in Advanced Cancer Patients
Pharmacyclics LLC.
Phase 1 Completed